This playbook outlines EU cGMP requirements, risk mitigation strategies, and bulk supply SOPs for pharma grade gelatin, helping teams avoid costly non
Pharma grade gelatin is a purified protein obtained by partial hydrolysis of collagen from animal connective tissue. It is manufactured and tested to meet the identity, purity, and functionality requirements that apply to pharmaceutical excipients. What distinguishes it is not simply higher gel strength or a cleaner appearance, but conformance to a compendial identity framework covering source, processing, composition, microbiological quality, chemical contaminants, and functional performance in a documented, reproducible manner.
Compendial identity separates pharmaceutical material from food or industrial gelatin through the complete quality package rather than any single visible property. A pharmaceutical-grade lot should be supported by batch documentation linking it to an approved animal source, manufacturing process, specification range, and test methods. Identity is established through protein-chemistry characteristics, including behavior under defined thermal and chemical conditions. Purity is assessed against limits for moisture, ash, sulfur dioxide, heavy metals or elemental impurities, residual processing aids, and microbial load. Food gelatin may share the same fundamental chemistry, but it is generally specified against food-industry requirements that do not necessarily address dosage-form performance, excipient traceability, or pharmaceutical microbiological expectations. Industrial gelatin is even less comparable, since its intended uses do not require the same purity, documentation, or bioburden controls.
For formulation teams, pharma grade gelatin should therefore be treated as a regulated excipient with a defined grade and intended use. A certificate of analysis provides lot-specific results, while supplier documentation supports source traceability and change control. The grade should be selected not by generic market naming, but by confirming that the material meets the monograph-based identity and purity criteria relevant to the finished drug product, together with the functional attributes required by the specific pharmaceutical process. Exact numerical ranges should be taken from the supplier's approved specification sheet or batch certificate; grade labels alone should not be treated as proof of suitability.
The technical behavior of pharma grade gelatin starts with the collagen source and hydrolysis route. Bovine and porcine materials are the most common mammalian origins; hide splits, bovine bone (ossein), and porcine skin are representative raw materials. Fish gelatin is also available for selected formulations, particularly where an alternative source is desired, but its gelation and melting behavior differ from mammalian gelatin owing to species-related amino-acid composition and collagen structure.
Gelatin is classified principally as Type A or Type B according to the pretreatment used before thermal extraction. Type A gelatin is produced by acid processing, commonly applied to porcine skin and certain hide materials. Acid pretreatment yields a material typically characterized by a higher isoionic point and often associated with pH values on the acidic side when measured in a standardized solution. Type B gelatin is produced by alkaline processing, commonly associated with bovine hide and bone; it generally has a lower isoionic point and a pH profile closer to neutral or mildly alkaline conditions. These labels describe process chemistry, not inherent product rank: both types can meet pharmaceutical-grade requirements when manufactured and controlled appropriately.
Source and process jointly influence molecular chain length, charge behavior, viscosity, gel strength, setting behavior, and compatibility with other formulation components. For example, hard capsule, softgel, tablet, and hydrogel applications may favor different combinations of gel strength, setting time, viscosity, and film flexibility. Bovine bone and hide gelatins are frequently evaluated where robust gel and film properties are required, while porcine Type A material is commonly considered for applications sensitive to its characteristic setting and rheological profile. Pharmaceutical suitability is therefore determined by documented source, process consistency, compendial compliance, and matched functional specifications rather than by source name alone.
Gelatin is predominantly protein and consists of water-soluble polypeptide chains released from collagen during hydrolysis. Its composition includes the amino acids characteristic of collagen, with glycine, proline, and hydroxyproline playing important roles in chain association and helix formation during cooling. Gelatin is not, however, a single molecular species. A commercial pharma grade gelatin lot contains a distribution of polypeptide chains and fragments, including higher-molecular-weight aggregates, intact or partially retained chain structures, and lower-molecular-weight peptides generated during processing.
Molecular weight distribution is a central determinant of functional behavior. As a general technical trend, larger chains and associated fractions offer more sites for intermolecular contact as the hot solution cools, supporting network formation, firmer gels, and cohesive films. Smaller fragments remain useful in solution but tend to reduce the effective connectivity of the gel network. This relationship is directional rather than a fixed quantitative rule: measured Bloom, viscosity, setting behavior, and film performance can also be affected by concentration, temperature history, pH, salts, plasticizers, other excipients, and the test method. As a result, two lots with similar protein content can behave differently if hydrolysis has shifted the balance between high- and low-molecular-weight fractions. Each batch should therefore be evaluated against its certificate of analysis and the user's process measurements.
For pharmaceutical manufacturers, this explains why protein purity alone is not a sufficient selection criterion. A capsule formulation depends on a reproducible balance between chain fractions so that dipping, setting, drying, and stripping remain controlled. A tablet binder requires predictable hydration and adhesion, while a hydrogel or specialized formulation may call for particular viscosity and gel-development characteristics. Batch consistency is supported by controlled raw-material selection, extraction conditions, hydrolysis extent, blending, and release testing. Pharma grade gelatin is therefore specified not only by chemical identity but also by functional evidence that the molecular weight distribution remains suitable for the intended dosage-form process.
The functional specification framework for pharma grade gelatin is built around measurable properties rather than descriptive grade names. Bloom strength is the standardized measure of gel rigidity, determined on a matured gel under defined concentration, temperature, and test conditions. It reflects the ability of gelatin to form a firm, self-supporting network and is a primary selection parameter for capsules and gelled formulations. High-Bloom material generally provides a stronger gel at equal concentration, but the appropriate Bloom depends on the dosage form; an unnecessarily high value can alter processing behavior just as an insufficient value can weaken capsule structure or setting performance.
Viscosity is measured on a standardized gelatin solution and reflects concentration-dependent flow behavior, molecular chain characteristics, and processing history. In capsule manufacturing, viscosity controls film thickness on dipping pins, solution transfer, bubble release, and uniformity. In softgels, it influences ribbon formation and sealing behavior; in tablet binding and liquid or semisolid formulations, it affects dispersion, hydration, and processability. pH is controlled because it affects chain charge, compatibility with active ingredients and dyes, viscosity stability, and interaction with other excipients. Type A and Type B gelatins occupy different characteristic pH ranges, so formulation compatibility must be evaluated with the actual grade.
Particle size matters for dry handling and dissolution. Granulated or coarser particles may flow and disperse more predictably, while finer particles hydrate quickly but can be more prone to clumping if added incorrectly. Particle distribution affects dusting, feeding, wetting, swelling, and dissolution time during solution preparation. Moisture, ash, sulfur dioxide, microbial limits, and contaminant controls complete the specification package. Hard capsules, softgels, tablet binders, coated systems, hydrogels, and specialized formulations therefore require different combinations of Bloom, viscosity, pH, and particle characteristics, selected against documented process requirements rather than a universal grade. Where a project requires numerical comparison, the appropriate ranges must be obtained from grade-specific supplier specifications and verified by lot testing rather than assumed from the dosage-form name.
Gelatin's pharmaceutical value arises from a reversible sol–gel transition. When pharma grade gelatin is dispersed and hydrated in water and then warmed, the polypeptide chains become mobile and form a solution. On cooling, chain segments reassociate into localized ordered regions and a continuous three-dimensional network that immobilizes water, producing a gel. Reheating disrupts these associations and returns the material toward a liquid state. This thermal reversibility is central to capsule formation, molding operations, and many gelatin-based delivery systems.
Gelation is governed by concentration, Bloom strength, molecular weight distribution, temperature history, cooling rate, pH, ionic environment, sugars, polyols, active ingredients, and other excipients. Setting speed influences manufacturing throughput and dimensional control. A system that sets too slowly may prolong processing or allow sagging and deformation; one that sets too rapidly may cause poor flow, incomplete mold filling, uneven films, or sealing difficulties. The melting profile is equally important because gelatin gels soften or melt over a temperature range rather than at a single sharp point. This behavior supports applications where the material must set during manufacture but later disperse, dissolve, or release the active substance under intended use conditions.
Film formation depends on the ability of gelatin chains to coalesce into a continuous layer and then dry into a cohesive membrane. Solution viscosity, surface behavior, drying conditions, plasticizers, and gelatin grade determine film thickness, flexibility, strength, transparency, and uniformity. In hard capsule manufacture, controlled dipping, setting, and drying produce the capsule shell; in softgels, gelatin, water, and plasticizer form a flexible ribbon that encloses the fill. In tablets, coatings, hydrogels, and specialized formulations, the same chain-association mechanism contributes to binding, barrier formation, matrix structure, or controlled-release behavior. Process control is therefore required at every stage from hydration to cooling and drying.
Pharma grade gelatin is used across dosage forms because it combines gelation, film formation, binding, water interaction, and thermal reversibility in one excipient. In two-piece hard capsules, gelatin solutions are formed into dried shells through controlled dipping, setting, drying, stripping, cutting, and joining. Bloom strength, viscosity, pH, particle dissolution behavior, and microbiological quality directly affect shell uniformity, mechanical integrity, and subsequent filling performance. Gelatin hard capsules are used to contain powders, granules, pellets, and other solid fills. A practical development sequence is to screen candidate grades by source and type, measure Bloom and viscosity under the intended solution conditions, run small-scale dipping or film trials, and then confirm shell weight, wall uniformity, setting response, drying behavior, and filling compatibility.
In softgels, gelatin is combined with water and a plasticizer to create a flexible ribbon that is formed and sealed around a liquid or semisolid fill. The gelatin grade must support ribbon strength, elasticity, seal integrity, and controlled drying without excessive brittleness or tackiness. Process-related observations commonly include ribbon cracking when gel strength or the moisture–plasticizer balance is unsuitable, sealing defects when viscosity or ribbon behavior is inconsistent, and residual tack or deformation when drying is not controlled. In tablet manufacturing, gelatin can serve as a binder in wet granulation or as a component in coating systems, where its film-forming and adhesive properties support granule strength or surface-layer formation. Compatibility with active ingredients, other binders, disintegrants, and processing conditions determines whether the gelatin contributes to robust tablets without undesirably delaying disintegration.
Gelatin also appears in hydrogel and wound-related matrix concepts because its hydrated network can provide structure and water retention. In such systems, concentration, Bloom, viscosity, pH, ionic environment, and cross-linking or formulation design govern gel firmness, swelling, and degradation behavior. In certain vaccine and biological formulations, gelatin has historically been used as a processing or stabilizing component in specific products, where protein excipients may help protect sensitive biological material during freezing, drying, or storage. Such use is product-specific and depends on formulation design, regulatory documentation, and compatibility evidence. Across these applications, the common principle is that the gelatin grade must be selected for its measured function in the finished drug product rather than treated as an interchangeable commodity.
Pharmaceutical-grade gelatin is differentiated from lower-grade material by a structured set of microbiological, chemical, and source-related safety controls. Because gelatin is a proteinaceous material of animal origin and is handled through aqueous processing, bioburden control is essential throughout manufacture. Incoming raw material, extraction, concentration, drying, milling, packaging, and storage environments can all affect microbial status. Typical pharmaceutical controls include defined limits for total aerobic microbial count, yeast and mold, and absence or restriction of specified objectionable organisms according to the applicable compendial and dosage-form requirements. The significance of a microbial limit depends on how the material is processed in the finished product; sterile and nonsterile applications do not present identical requirements.
Chemical controls address residues and impurities that may remain after processing. These commonly include moisture, total ash, insoluble ash, sulfur dioxide or related sulfite residues, hydrogen peroxide or other processing aids where used, heavy metals or elemental impurities, and contaminants associated with water or equipment. Excipient manufacturers use validated processing steps, water control, filtration, ion exchange or other purification treatments, evaporation, drying under controlled conditions, and documented release testing to manage these attributes. Batch certificates provide lot-specific results against approved specifications, while change control helps prevent unreported process or source changes.
BSE/TSE risk management is a particularly important consideration for bovine and other animal-derived gelatin. Control is based on source traceability, animal-health status, collection of approved raw materials, exclusion of specified high-risk tissues where required, and validated processing under applicable regulatory expectations. Gelatin from bovine hide or bone is not assessed by source alone; the supplier's sourcing system, documentation, and processing history are part of the evaluation. Porcine, fish, or other origins do not automatically remove the need for source and quality controls.
A supplier and incoming-lot file can be organized as a documentation checklist rather than treated as evidence beyond what the supplier actually provides:
Formulators should retain documentation appropriate to the product's regulatory pathway rather than infer safety from grade labeling.
Successful use of pharma grade gelatin begins before the bag or container is opened. Incoming material should be reconciled against the approved supplier, grade, type, source, lot number, packaging integrity, and certificate of analysis. Relevant tests may include identity, Bloom strength, viscosity, pH, moisture, particle size, ash, sulfur dioxide, and microbiological attributes, depending on the dosage form and internal qualification policy. Some users perform confirmatory testing on every lot; others verify critical functional parameters based on risk, supplier qualification, and process sensitivity.
Solution preparation must distinguish wetting, swelling, and dissolution. Dry gelatin particles should normally be dispersed into water under conditions that prevent clumping, then allowed to hydrate before controlled heating. Adding water to a concentrated mass of fine gelatin or applying heat too early can produce lumps with dry cores and misleading viscosity readings. The required temperature, hold time, agitation, and water quality depend on gelatin grade, concentration, particle size, and downstream process. Prolonged or excessive heating can reduce molecular weight through thermal or hydrolytic degradation, lowering Bloom strength and viscosity and changing setting behavior. Vacuum processing, deaeration, and filtration may be used to remove bubbles or insoluble matter in capsule and film operations.
Processing can be managed through defined checkpoints without assuming universal temperature or time values:
Incoming handling and processing discipline therefore directly preserve the functional specifications established during gelatin manufacture.
Pharma grade gelatin should be stored in sealed, intact packaging under dry, clean, well-ventilated conditions that protect it from moisture, heat, direct sunlight, odors, dust, pests, and microbial contamination. Although gelatin is supplied as a dried material, it is hygroscopic and can exchange moisture with the surrounding atmosphere. Exposure to high humidity can increase water content, promote caking or lumping, accelerate microbial risk, and alter handling. Excessive dryness is not necessarily beneficial either, because very low moisture in finished gelatin films can contribute to brittleness, especially when the plasticizer balance is inadequate. The objective is to maintain the material within the moisture range established for the grade and packaging system.
Temperature control supports both chemical and functional stability. Prolonged storage near heat sources can cause packaging deterioration, localized moisture migration, and premature quality changes, while wet or unsanitary conditions increase the risk of mold or bacterial contamination. Pallets should be kept off the floor and away from walls, and stock should be rotated according to documented receipt and expiry dates. Once a container is opened, material should be resealed promptly and used under controlled conditions; repeated exposure to processing-room humidity can change particle flow, dissolution behavior, and microbiological status.
Shelf life is not a generic fixed value. It is established by the supplier based on packaging, gelatin type, moisture content, storage conditions, stability data, and quality risk assessment. Users should follow the labeled retest or expiry period rather than transferring a shelf life from one supplier or grade to another. Stability-relevant changes include caking, off-odor, abnormal color, elevated bioburden, moisture shift, reduced Bloom, viscosity drift, poor dissolution, and inconsistent setting. Finished capsules and softgels also require controlled drying and equilibrium moisture management because shell brittleness or tackiness can result from moisture imbalance. A documented storage, stock-rotation, inspection, and retest program helps preserve both safety attributes and functional performance throughout the declared use period.
Pharma grade gelatin is defined by compendial identity, documented animal-source traceability, purity controls, and dosage-form-specific functional performance, rather than by appearance or generic market naming. Bovine, porcine, and fish origins, together with acid-produced Type A and alkaline-produced Type B processes, create measurable differences in pH behavior, molecular weight distribution, viscosity, gelation, and film properties. Bloom strength, viscosity, pH, particle size, moisture, and contaminant limits provide the practical specification framework for selecting material for hard capsules, softgels, tablets, hydrogels, and specialized biological formulations. Molecular-weight and performance relationships should be treated as general trends, with each batch confirmed by measured results. Its reversible sol–gel transition and film-forming behavior depend on concentration, temperature history, cooling, drying, plasticizers, and compatibility with active ingredients and other excipients. Microbiological, chemical, and BSE/TSE controls should be supported by organized supplier documentation and incoming verification, while controlled hydration, dissolution, processing checkpoints, dry storage, stock rotation, and shelf-life management preserve the measured properties that allow bovine gelatin and other pharmaceutical grades to perform consistently in pharmaceutical manufacturing.
Approvisionnement et éligibilité des tissus porcins pour la production de gélatine pharmaceutique La qualité de la gélatine porcine de grade pharmaceutique est déterminée bien avant l’étape d’extracti
Mis à jour sept. 2026Classification des matières premières osseuses de qualité alimentaire pour la production de gélatine Dans la fabrication industrielle de gélatine, l’os de qualité alimentaire n’est pas considéré comme
Mis à jour sept. 2026Maîtrise des matières premières pour la gélatine porcine alimentaire destinée aux usages adjacents à la pharmacie La qualité de la gélatine porcine de qualité alimentaire dépend d’abord de la maîtrise
Mis à jour sept. 2026Force Bloom et rigidité du gel de la gélatine bovine à gélification rapide Dans la catégorie intermédiaire des gélatines bovines à gélification rapide, la force Bloom constitue la spécification princi
Mis à jour sept. 2026Distribution des masses moléculaires et mécanisme de gélification rapide de la gélatine bovine La prise en gel rapide de la gélatine bovine repose sur une distribution étroitement maîtrisée des masses
Mis à jour sept. 2026Définition de la gélatine alimentaire et frontière avec les matières à usage pharmaceutique La gélatine alimentaire est une protéine comestible obtenue par hydrolyse partielle du collagène, protéine s
Mis à jour sept. 2026Chez BEYOND BIOPHARMA, nous nous considérons comme une extension de votre équipe R&D. Nous fournissons une documentation technique complète, des données de stabilité et des échantillons adaptés pour accélérer le développement de votre produit, de la conception à sa mise sur le marché, grâce à notre expertise éprouvée.
Êtes-vous prêt à découvrir la différence que font 20 ans de précision ?
